Monopar Therapeutics Inc. (MNPR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Monopar Therapeutics Inc. (MNPR) closed at USD 73.10 on 2026-10-14, a change of -8.5 % over the past year, with a market capitalization of USD 481.93M.

Monopar Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Monopar Therapeutics Inc. key figures

Previous close

USD 73.10 (2026-10-14)

1-year change

-8.5 %

Market cap

USD 481.93M

Enterprise value

USD 347.84M

P/E ratio (trailing)

-32.64

P/E ratio (forward)

-37.48

EPS (trailing)

-2.20

EPS (forward)

-1.92

PEG ratio

n/a

Price to book

3.68

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.15

Employees

22

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Monopar Therapeutics Inc. and compare it with other stocks.